Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis
Abstract
An iron efflux pump is a pivotal protein in breast cancer biology and a strong and independent predictor of breast cancer prognosis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both p53 and FOXO control a distinct set of genes that are not targets of Nrf2, even though all three factors induce HMOX1 expression and Fe(II) storage and secretion, which plays a role in breast tumorigenesis, highlighting the role of antioxidants in cancer promotion.
“Interestingly, both p53 and FOXO control a distinct set of genes that are not targets of Nrf2 activity, even though all three factors induce HMOX1 expression and, therefore, Fe(II) storage and secretion, that plays a role in breast tumorigenesis, highlighting the role of antioxidants in cancer promotion28.”
From ROS in cancer therapy: the bright side of the moon (2020) · cites this paper as [28]
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredCancer cells have increased expression of transferrin receptor-1, a higher rate of iron uptake from transferrin, and decreased expression of iron exporters.
“Thus, cancer cells have increased expression of transferrin receptor-1 and a higher rate of iron uptake from transferrin [55, 56], as well as decreased expression of iron exporters [57].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [57]
Higher concentrations of free iron in breast cancer cells are associated with a more aggressive tumor phenotype.
“Interestingly, higher concentrations of free iron in breast cancer cells are associated with a more aggressive tumor phenotype [57].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [57]
In invasive tumor areas, iron export via FPN is lower compared to normal tissue.
“In invasive tumor areas, iron export via FPN is lower compared to normal tissue, with the notion that FPN expression in carcinomas inversely correlated with patient survival and disease outcome [42].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [42]
FPN expression in carcinomas inversely correlated with patient survival and disease outcome.
“In invasive tumor areas, iron export via FPN is lower compared to normal tissue, with the notion that FPN expression in carcinomas inversely correlated with patient survival and disease outcome [42].”
From Iron as a central player and promising target in cancer progression (2019) · cites this paper as [42]
Hepcidin generated by breast or prostate cancer epithelial cells promotes iron retention via autocrine degradation of ferroportin, which favors survival and growth.
“For instance, hepcidin generated by breast or prostate cancer epithelial cells promotes iron retention via autocrine degradation of ferroportin, which in turn favors survival and growth (Pinnix et al., 2010; Tesfay et al., 2015).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Pinnix et al., 2010
Breast cancer cells have about double the intracellular labile Fe2+ pool of normal breast epithelial cells.
“the pool of intracellular labile Fe2+ in breast cancer cells is approximately twice as high as in normal breast epithelial cells39.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
1 retracted
RETRACTED: The Hepcidin-Binding Site on Ferroportin Is Evolutionarily Conserved
Domenico, I. D., Nemeth, E., Nelson, J. M., Phillips, J. D., Ajioka, R. S., Kay, M. S., Kushner, J. P., Ganz, T., Ward, D. M., & Kaplan, J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.002 · Cited by 127 · see citing works
RetractedSørlie, T., Perou, C., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M., van de Rijn, M., Jeffrey, S., et al. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.191367098 · Cited by 11,695 · see citing works
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., Veer, L. V. ‘., Dai, H. A., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,411 · see citing works
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,009 · see citing works
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R. J., Parker, J. S., Hastie, T. J., Marron, J. S., Nobel, A. B., Deng, S., Johnsen, H., Pesich, R., Geisler, S. B., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,428 · see citing works
Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization
Nemeth, E., Tuttle, M. S., Powelson, J., Vaughn, M. B., Donovan, A., Ward, D. M., Ganz, T., & Kaplan, J. (2004) · Science · doi:10.1126/science.1104742 · Cited by 4,803 · see citing works
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,737 · see citing works
Rhodes, D. R., Sundaram, S. K., Mahavisno, V., Varambally, R., Yu, J., Briggs, B., Barrette, T. R., Anstett, M. J., Kincead-Beal, C., Kulkarni, P., et al. (2007) · Neoplasia · doi:10.1593/neo.07112 · Cited by 2,064 · see citing works
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667 · see citing works
Soule, H. D., Maloney, T., Wolman, S. R., Peterson, W., Brenz, R., McGrath, C. M., Russo, J., Pauley, R. J., Jones, R. F., & Brooks, S. C. (1990) · PubMed · Cited by 1,527 · see citing works
Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J. E., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,499 · see citing works
McKie, A. T., Marciani, P., Rolfs, A., Brennan, K., Wehr, K., Barrow, D., Miret, S., Bomford, A., Peters, T. J., Farzaneh, F., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80425-6 · Cited by 1,422 · see citing works
The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis
Donovan, A., Lima, C. A., Pinkus, J. L., Pinkus, G. S., Zon, L. I., Robine, S., & Andrews, N. C. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.01.003 · Cited by 1,275 · see citing works
Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L. A., Ploner, A., Yudi Pawitan, Y., Hall, P. N., Klaar, S., Liu, E. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506230102 · Cited by 1,269 · see citing works
Self-citationA Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism
Abboud, S., & Haile, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000713200 · Cited by 1,267 · see citing works
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878 · see citing works
Kakhlon, O., & Cabantchik, Z. I. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01006-7 · Cited by 839 · see citing works
Loi, S., Haibe‐Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A. L., Bergh, J. C. S., Foekens, J. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1522 · Cited by 836 · see citing works
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756 · cited 1× · see citing works
“Our results are concordant with emerging evidence of the importance of ferroportin in ironhomeostasis, both at an organismal level in transmitting the signals from hepcidin to the systemic iron-regulatory network (46) and in regulating iron homeostasis in cells (17).”
Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer
Ivshina, A. V., George, J., Sen'ko, O. V., Mow, B. M. F., Putti, T. C., Smeds, J., Lindahl, T., Yudi Pawitan, Y., Hall, P. N., Nordgren, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4414 · Cited by 751 · see citing works
Self-citationDaniels‐Wells, T. R., Delgado, T., Rodríguez, J. A., Helguera, G. F., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.010 · Cited by 630 · see citing works
The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells
Daniels‐Wells, T. R., Delgado, T., Helguera, G. F., & Penichet, M. L. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.06.006 · Cited by 519 · see citing works
Whitnall, M., Howard, J., Ponka, P., & Richardson, D. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604979103 · Cited by 510 · see citing works
The Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation
De Domenico, I., Ward, D. M., Langelier, C., Vaughn, M. B., Nemeth, E., Sundquist, W. I., Ganz, T., Musci, G., & Kaplan, J. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-01-0060 · Cited by 434 · see citing works
Estrogen Receptor in a Human Cell Line (MCF-7) from Breast Carcinoma
Brooks, S., Locke, E. R., & Soule, H. D. (1973) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)43537-0 · Cited by 416 · see citing works
Coordinated Regulation of Iron-Controlling Genes, H-Ferritin and IRP2 , by c-MYC
Wu, K., Polack, A., & Dalla‐Favera, R. (1999) · Science · doi:10.1126/science.283.5402.676 · Cited by 328 · see citing works
Marro, S., Chiabrando, D., Messana, E., Stolte, J., Turco, E., Tolosano, E., & Muckenthaler, M. U. (2010) · Haematologica · doi:10.3324/haematol.2009.020123 · Cited by 297 · see citing works
Zhang, D.-L., Hughes, R. M., Ollivierre-Wilson, H., Ghosh, M. C., & Rouault, T. A. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.03.006 · Cited by 281 · see citing works
Transferrin and transferrin receptors in carcinoma of the breast
Page Faulk, W., Hsi, B.-L., & Stevens, P. J. (1980) · The Lancet · doi:10.1016/s0140-6736(80)90440-7 · Cited by 280 · see citing works
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients
Calza, S., Hall, P. N., Auer, G., Bjöhle, J., Klaar, S., Kronenwett, U., Liu, E. T., Miller, L. D., Ploner, A., Smeds, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1517 · Cited by 263 · see citing works
Self-citationA precious metal: Iron, an essential nutrient for all cells
Cairo, G., Bernuzzi, F., & Recalcati, S. (2006) · Genes & Nutrition · doi:10.1007/bf02829934 · Cited by 252 · see citing works
The Role of Iron Chelation in Cancer Therapy
Buss, J. L., Torti, F. M., & Torti, S. V. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457638 · Cited by 236 · see citing works
Self-citationThelander, L., Gräslund, A., & Thelander, M. (1983) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(83)91040-9 · Cited by 187 · see citing works
Sartor, C. I., Dziubinski, M. L., Yu, C., et al. (1997) · PubMed · Cited by 186 · see citing works
The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression
Lymboussaki, A., Pignatti, E., Montosi, G., Garuti, C., Haile, D. J., & Pietrangelo, A. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00408-2 · Cited by 177 · see citing works
Regulation of Hepcidin and Iron-Overload Disease
Lee, P. L., & Beutler, E. (2009) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092205 · Cited by 174 · see citing works
Rao, V. A., Klein, S. R., Agama, K., Toyoda, E., Adachi, N., Pommier, Y. G., & Shacter, E. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1437 · Cited by 155 · see citing works
Boult, J. K. R., Roberts, K., Brookes, M., Hughes, S., Bury, J. P., Cross, S. S., Anderson, G. J., Spychal, R., Iqbal, T. H., & Tselepis, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1054 · Cited by 132 · see citing works
RCP is a human breast cancer–promoting gene with Ras-activating function
Zhang, J., Liu, X., Datta, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37622 · Cited by 120 · see citing works
Karp, J. E., Giles, F. J., Gojo, I., et al. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.05.003 · Cited by 98 · see citing works
Green, D. A., Antholine, W. E., Wong, S. J., Richardson, D. R., & Chitambar, C. R. (2001) · PubMed · Cited by 90 · see citing works
The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1)
McKie, A. T., & Barlow, D. J. (2004) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-003-1102-3 · Cited by 86 · see citing works
PIASy-Mediated Sumoylation of Yin Yang 1 Depends on Their Interaction but Not the RING Finger
Deng, Z., Wan, M., & Sui, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01761-06 · Cited by 86 · see citing works
Self-citationHall, P. N., Ploner, A., Bjöhle, J., et al. (2006) · BMC Medicine · doi:10.1186/1741-7015-4-16 · Cited by 69 · see citing works
Maffettone, C., Chen, G., Drozdov, I. A., Ouzounis, C. A., & Pantopoulos, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010163 · Cited by 68 · see citing works
Overexpression of iron regulatory protein 1 suppresses growth of tumor xenografts
Chen, G., Fillebeen, C., Wang, J., & Pantopoulos, K. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl210 · Cited by 55 · see citing works
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines
Ignatoski, K. M. W., & Ethier, S. P. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006135331912 · Cited by 50 · see citing works
Expression of iron regulatory genes in a rat model of hepatocellular carcinoma
Holmström, P., Gåfvels, M. E., Eriksson, L. C., Dzikaite, V., Hultcrantz, R. W., Eggertsen, G., & Stal, P. I. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01316.x · Cited by 44 · see citing works
Kakhlon, O., Gruenbaum, Y., & Cabantchik, Z. I. (2002) · Biochemical Journal · doi:10.1042/0264-6021:3630431 · Cited by 44 · see citing works
Preferential repression of the H subunit of ferritin by adenovirus E1A in NIH-3T3 mouse fibroblasts.
Tsuji, Y., Kwak, E. L., Saika, T., Torti, S. V., & Torti, F. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53172-0 · Cited by 43 · see citing works
Self-citationLeong, W.-I., & Lönnerdal, B. L. (2005) · American Journal of Clinical Nutrition · doi:10.1093/ajcn.81.2.445 · Cited by 35 · see citing works
Kakhlon, O., Gruenbaum, Y., & Cabantchik, Z. I. (2002) · Biochemical Journal · doi:10.1042/bj3630431 · Cited by 30 · see citing works
Winter, J. L., Stackhouse, B. L., Russell, G. B., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-767-mopeut · Cited by 15 · see citing works
Chen, S., Zhu, B., & Yu, L. (2005) · Cytogenetic and Genome Research · doi:10.1159/000087513 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691 · see citing works
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579 · see citing works
ROS in cancer therapy: the bright side of the moon
Perillo, B., Di Donato, M., Pezone, A., Di Zazzo, E., Giovannelli, P., Galasso, G., Castoria, G., & Migliaccio, A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0384-2 · Cited by 2,176 · see citing works
Iron and cancer: more ore to be mined
Torti, S. V., & Torti, F. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3495 · Cited by 1,621 · see citing works
Self-citationIron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507 · see citing works
Self-citationMammalian iron metabolism and its control by iron regulatory proteins
Anderson, C. P., Shen, M., Eisenstein, R. S., & Leibold, E. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.05.010 · Cited by 493 · see citing works
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N., & Torti, F. M. (2018) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082117-051732 · Cited by 426 · see citing works
Targeting cancer vulnerabilities with high-dose vitamin C
Ngo, B., Van Riper, J. M., Cantley, L. C., & Yun, J. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0135-7 · Cited by 423 · see citing works
Lipocalin 2: an emerging player in iron homeostasis and inflammation
Xiao, X., Yeoh, B. S., & Vijay-Kumar, M. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064559 · Cited by 426 · see citing works
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352 · see citing works
Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype.
Cairo, G., Recalcati, S., Mantovani, A., & Locati, M. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.03.007 · Cited by 312 · see citing works
Iron as a central player and promising target in cancer progression
Jung, M., Mertens, C., Tomat, E., & Brüne, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020273 · Cited by 268 · see citing works
“In invasive tumor areas, iron export via FPN is lower compared to normal tissue, with the notion that FPN expression in carcinomas inversely correlated with patient survival and disease outcome [42].”
An iron regulatory gene signature predicts outcome in breast cancer
Miller, L. D., Coffman, L. G., Chou, J. W., Black, M. A., Bergh, J., D'Agostino, R., Torti, S. V., & Torti, F. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1870 · Cited by 202 · see citing works
Iron and Reactive Oxygen Species: Friends or Foes of Cancer Cells?
Bystrom, L. M., Guzman, M. L., & Rivella, S. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5014 · Cited by 212 · see citing works
Hepcidin regulation in prostate and its disruption in prostate cancer
Tesfay, L., Clausen, K. A., Kim, J. W., Hegde, P., Wang, X., Miller, L. D., Deng, Z., Blanchette, N., Arvedson, T., Miranti, C. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2465 · Cited by 186 · see citing works
Self-citationIron induces anti-tumor activity in tumor-associated macrophages
Costa da Silva, M., Breckwoldt, M. O., Vinchi, F., Correia, M. P., Stojanovic, A., Thielmann, C. M., Meister, M., Muley, T., Warth, A., Platten, M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01479 · Cited by 164 · see citing works
Torti, S. V., & Torti, F. M. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100860 · Cited by 153 · see citing works
Self-citationCoupling Heme and Iron Metabolism <i>via</i> Ferritin H Chain
Gozzelino, R., & Soares, M. P. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5666 · Cited by 151 · see citing works
Iron in the Tumor Microenvironment-Connecting the Dots
Pfeifhofer-Obermair, C., Tymoszuk, P., Petzer, V., Weiss, G., & Nairz, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00549 · Cited by 151 · see citing works
The Role of Iron in Cancer Progression
Guo, Q., Li, L., Hou, S., Yuan, Z., Li, C., Zhang, W., Zheng, L., & Li, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.778492 · Cited by 150 · see citing works
Pharmacological Targeting of the Hepcidin/Ferroportin Axis
Sebastiani, G., Wilkinson, N., & Pantopoulos, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00160 · Cited by 127 · see citing works
‘Ride on the ferrous wheel’ – The cycle of iron in macrophages in health and disease
Nairz, M., Schroll, A., Demetz, E., Tancevski, I., Theurl, I., & Weiss, G. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.010 · Cited by 89 · see citing works
Local iron homeostasis in the breast ductal carcinoma microenvironment
Marques, O., Porto, G., Rêma, A., Faria, F., Cruz Paula, A., Gomez-Lazaro, M., Silva, P., Martins da Silva, B., & Lopes, C. (2016) · BMC Cancer · doi:10.1186/s12885-016-2228-y · Cited by 90 · see citing works
Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment
Mertens, C., Mora, J., Ören, B., Grein, S., Winslow, S., Scholich, K., Weigert, A., Malmström, P., Forsare, C., Fernö, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1408751 · Cited by 85 · see citing works
Jézéquel, P., Campion, L., Spyratos, F., Loussouarn, D., Campone, M., Guérin‐Charbonnel, C., Joalland, M., André, J., Descotes, F., Grenot, C., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26397 · Cited by 85 · see citing works
Mertens, C., Akam, E. A., Rehwald, C., Brüne, B., Tomat, E., & Jung, M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166164 · Cited by 83 · see citing works
Chua, A. C. G., Klopcic, B. R. S., Ho, D. S., Fu, S. K., Forrest, C. H., Croft, K. D., Olynyk, J. K., Lawrance, I. C., & Trinder, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078850 · Cited by 76 · see citing works
Leishmania-Mediated Inhibition of Iron Export Promotes Parasite Replication in Macrophages
Ben-Othman, R., Flannery, A. R., Miguel, D. C., Ward, D. M., Kaplan, J., & Andrews, N. W. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003901 · Cited by 76 · see citing works
Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer
Orlandi, R., De Bortoli, M., Ciniselli, C. M., Vaghi, E., Caccia, D., Garrisi, V., Pizzamiglio, S., Veneroni, S., Bonini, C., Agresti, R., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt490 · Cited by 74 · see citing works
The utility of iron chelators in the management of inflammatory disorders
Lehmann, C., Islam, S., Jarosch, S., Zhou, J., Hoskin, D., Greenshields, A., Al-Banna, N., Sharawy, N., Sczcesniak, A., Kelly, M., et al. (2015) · Mediators of Inflammation · doi:10.1155/2015/516740 · Cited by 54 · see citing works
“Interestingly, higher concentrations of free iron in breast cancer cells are associated with a more aggressive tumor phenotype [57].”
BackgroundKamihara, Y., Takada, K., Sato, T., Kawano, Y., Murase, K., Arihara, Y., Kikuchi, S., Hayasaka, N., Usami, M., Iyama, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11830 · Cited by 45 · see citing works
Identification of Antibody and Small Molecule Antagonists of Ferroportin-Hepcidin Interaction
Ross, S. L., Biswas, K., Rottman, J., Allen, J. R., Long, J., Miranda, L. P., Winters, A., & Arvedson, T. L. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00838 · Cited by 33 · see citing works
Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in <i>KRAS</i> -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33 · see citing works
Dietary and Sentinel Factors Leading to Hemochromatosis
Oh, C.-K., & Moon, Y. (2019) · Nutrients · doi:10.3390/nu11051047 · Cited by 12 · see citing works
- Authors
- Pinnix, Z. K., Miller, L. D., Wang, W., D’Agostino, R., Kute, T., Willingham, M. C., Hatcher, H., Tesfay, L., Sui, G., Di, X., Torti, S. V., & Torti, F. M.
- Affiliations
- Wake Forest University Health Sciences (US)
- Corresponding author
- Torti, Frank M.
- Venue
- Science Translational Medicine
- Published
- 2010-08-04
- Volume
- 2
- Issue
- 43
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4233526312
- Cited by
- 448
- References
- 54
- Citations by year
- 2026: 22 · 2025: 28 · 2024: 29 · 2023: 37 · 2022: 35 · 2021: 44 · 2020: 43 · 2019: 34 · 2018: 32 · 2017: 30 · 2016: 18 · 2015: 16 · 2014: 29 · 2013: 21 · 2012: 17
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- Funders
- National Cancer Institute (R01CA171101)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK071892, R37DK042412)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- ferroportin, iron regulation, breast cancer, iron efflux, tumor progression, prognosis, prognostic factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
